Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

67.72 -1.23 (-1.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
From AstraZeneca
Via Business Wire
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
Via FinancialNewsMedia
Exposures COVID-19
IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
From AstraZeneca
Via Business Wire
IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
From AstraZeneca
Via Business Wire
Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials
From AstraZeneca
Via Business Wire
FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) Vaccine Now Available in the US for Annual Flu Season
From AstraZeneca
Via Business Wire
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) significantly improved progression-free survival in DESTINY-Breast03 head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2
From AstraZeneca
Via Business Wire
SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus
From AstraZeneca
Via Business Wire
BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
From AstraZeneca
Via Business Wire
Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma
From AstraZeneca
Via Business Wire
Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes
From AstraZeneca
Via Business Wire
CALQUENCE Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia and Sustained Patient Benefit at Four Years in the Front-line Setting
From AstraZeneca
Via Business Wire
IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years
From AstraZeneca
Via Business Wire
LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience
From AstraZeneca
Via Business Wire
New FASENRA® Data From the MELTEMI Extension Trial Confirm Long-Term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years
From AstraZeneca
Via Business Wire
New Tezepelumab Data Continue to Strengthen Profile for a Broad Population of Severe Asthma Patients
From AstraZeneca
Via Business Wire
NASDAQ: AZN Long Term Investor Notice: Investigation of Potential Wrongdoing at AstraZeneca PLC
San Diego, CA -- (SBWIRE) -- 05/10/2021 -- An investigation on behalf of current long term investors in AstraZeneca PLC (NASDAQ: AZN) shares over possible breaches of fiduciary duty by certain officers... 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
IMFINZI and tremelimumab With Chemotherapy Demonstrated Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer
From AstraZeneca
Via Business Wire
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
Via FinancialNewsMedia
Topics Death
Exposures Death
FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes
From AstraZeneca
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.